Joanne L Jones

List of Publications by Year in Descending Order

57 papers	2,916 citations	25 h-index	54 g-index
66 ext. papers	3,605 ext. citations	8 avg, IF	4.74 L-index

#	Paper	IF	Citations
57	Cross-tissue immune cell analysis reveals tissue-specific features in humans.. *Science*, **2022**, 376, eabl5197	33.3	13
56	Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73. *Communications Biology*, **2021**, 4, 1186	6.7	0
55	Immunological considerations and challenges for regenerative cellular therapies. *Communications Biology*, **2021**, 4, 798	6.7	14
54	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. *Journal of Immunology*, **2021**,	5.3	6
53	Neuroanatomical substrates of generalized brain dysfunction in COVID-19. *Intensive Care Medicine*, **2021**, 47, 116-118	14.5	7
52	The yin and yang of intracellular reactive oxygen species following T-cell activation. *Brain*, **2021**, 144, 2909-2911	11.2	
51	The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation. *Frontiers in Immunology*, **2021**, 12, 712241	8.4	2
50	The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease. *Neuronal Signaling*, **2021**, 5, NS20200083	3.7	
49	Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. *Lancet Neurology, The*, **2021**, 20, 709-720	24.1	6
48	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. *Multiple Sclerosis Journal*, **2021**, 1352458521061335	5	1
47	Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	2
46	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. *Brain, Behavior, and Immunity*, **2020**, 87, 473-488	16.6	29
45	Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. *Genome Medicine*, **2020**, 12, 55	14.4	24
44	Distinct microbial and immune niches of the human colon. *Nature Immunology*, **2020**, 21, 343-353	19.1	92
43	Transcript specific regulation of expression influences susceptibility to multiple sclerosis. *European Journal of Human Genetics*, **2020**, 28, 826-834	5.3	4
42	Detection limit of Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI. *EJNMMI Research*, **2020**, 10, 82	3.6	5
41	Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. *Multiple Sclerosis Journal*, **2020**, 26, 1093-1101	5	5

40	Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis. *Journal of Neurology*, **2019**, 266, 1539-1540	5.5	1
39	2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy. *European Thyroid Journal*, **2019**, 8, 173-185	4.2	20
38	Keratinocyte growth factor impairs human thymic recovery from lymphopenia. *JCI Insight*, **2019**, 5,	9.9	10
37	A case of anaphylaxis to alemtuzumab. *Journal of Neurology*, **2019**, 266, 780-781	5.5	1
36	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. *JAMA - Journal of the American Medical Association*, **2019**, 321, 175-187	27.4	172
35	Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. *Brain*, **2018**, 141, 786-796	11.2	23
34	Extracellular Lactate: A Novel Measure of T Cell Proliferation. *Journal of Immunology*, **2018**, 200, 1220-1226	5.5	17
33	Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. *Neurology*, **2018**, 90, 849-851	6.5	25
32	Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from Na-MRI. *Journal of the Neurological Sciences*, **2018**, 387, 111-114	3.2	4
31	Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 3010-3018	5.6	35
30	Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis. *Frontiers in Neurology*, **2018**, 9, 870	4.1	22
29	Sarcoidosis following alemtuzumab treatment for multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 24, 1779-1782	5	21
28	Meeting abstracts from the 64th British Thyroid Association Annual Meeting. *Thyroid Research*, **2017**, 10,	2.4	2
27	Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. *JCI Insight*, **2017**, 2,	9.9	26
26	Progressive multifocal leucoencephalopathy with Behçet's disease: an insight into pathophysiology. *Rheumatology*, **2017**, 56, 668-670	3.9	0
25	Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. *Journal of Neurology*, **2016**, 263, 25-9	5.5	33
24	Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis. *PLoS ONE*, **2016**, 11, e0158327	3.7	3
23	Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 208-15	5.5	164

22	Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 708-13	5.5	81
21	Mode of action and clinical studies with alemtuzumab. *Experimental Neurology*, **2014**, 262 Pt A, 37-43	5.7	43
20	Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. *Neurology*, **2014**, 82, 2158-64	6.5	44
19	Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 795-8	5.5	34
18	Immune competence after alemtuzumab treatment of multiple sclerosis. *Neurology*, **2013**, 81, 872-6	6.5	95
17	Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. *Brain*, **2013**, 136, 2888-903	11.2	130
16	Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 20200-5	11.5	149
15	Targeting CD52 for the Treatment of Multiple Sclerosis **2013**, 385-399		
14	Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. *Expert Review of Neurotherapeutics*, **2012**, 12, 335-41	4.3	65
13	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 298-304	5.5	148
12	Radiologically compatible CLIPPERS may conceal a number of pathologies. *Brain*, **2011**, 134, e187	11.2	22
11	A novel strategy to reduce the immunogenicity of biological therapies. *Journal of Immunology*, **2010**, 185, 763-8	5.3	58
10	Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. *Brain*, **2010**, 133, 2232-47	11.2	131
9	New treatment strategies in multiple sclerosis. *Experimental Neurology*, **2010**, 225, 34-9	5.7	31
8	B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. *Journal of Clinical Immunology*, **2010**, 30, 99-105	5.7	180
7	IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). *Journal of Clinical Investigation*, **2009**, 119, 2052-61	15.9	215
6	Campath-1H treatment of multiple sclerosis. *Neurodegenerative Diseases*, **2008**, 5, 27-31	2.3	30
5	The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. *Journal of Neurology*, **2006**, 253, 98-108	5.5	401

4	Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. *European Journal of Immunology*, **2005**, 35, 3332-42	6.1	248
3	Recent thymic emigrants produce antimicrobial IL-8, express complement receptors and are precursors of a tissue-homing Th8 lineage of memory cells		1
2	Cross-tissue immune cell analysis reveals tissue-specific adaptations and clonal architecture in humans		9
1	The MS remyelinating drug bexarotene (an RXR agonist) promotes induction of human Tregs and suppresses Th17 differentiation in vitro		1